Table 1.
Baseline characteristics and weight, waist circumference and lipid profiles at baseline and following exposure to mirtazapineA
| Baseline | Post-intervention | Z | PB | Mean change | 95% CI | |||
|---|---|---|---|---|---|---|---|---|
| M | SD | M | SD | |||||
| Age (years) | 22.3 | 1.5 | ||||||
| Height (cm) | 180.7 | 6.9 | ||||||
| Weight (kg) | 74.4 | 5.9 | 73.8 | 5.8 | – 3.1 | 0.002 | – 0.6 | 0.4; 0.8 |
| Body-mass-index (kg/m2) | 22.8 | 1.6 | 22.6 | 1.6 | – 3.1 | 0.002 | – 0.2 | 0.1; 0.2 |
| Waist circumference (cm) | 78.9 | 4.2 | 78.5 | 2.9 | – 0.2 | 0.838 | – 0.4 | – 2.1; 2.9 |
| Waist/hip ratio | 0.9 | 0.0 | 0.9 | 0.0 | – 0.2 | 0.814 | 0.0 | – 0.0; 0.0 |
| Total cholesterol (mg/dl) | 146.6 | 25.1 | 134.3 | 21.1 | – 2.8 | 0.005 | – 12.3 | 5.4; 19.1 |
| Triglycerides (mg/dl) | 64.0 | 19.3 | 68.4 | 17.4 | – 2.0 | 0.044 | 4.4 | – 11.4; 2.6 |
| HDL-C (mg/dl) | 47.5 | 5.6 | 43.3 | 5.5 | – 2.9 | 0.004 | – 4.3 | 2.1; 6.5 |
| LDL-C (mg/dl) | 85.8 | 20.8 | 77.2 | 17.2 | – 2.7 | 0.008 | – 8.7 | 3.8; 13.5 |
| Non-HDL-C (mg/dl) | 99.0 | 23.4 | 91.1 | 19.4 | – 2.3 | 0.023 | – 8.0 | 1.9; 14.0 |
| TG/HDL-C | 1.4 | 0.4 | 1.6 | 0.5 | – 2.4 | 0.019 | 0.2 | – 0.4; 0.1 |
AData (n = 12) are mean values (M) and standard deviations (SD).
BTwo-sided significance p < 0.05 is in bold (two-sided Wilcoxon signed rank test).